Artwork

محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !

Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

51:25
 
اشتراک گذاری
 

Manage episode 352264837 series 2771425
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Go online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investigations are underway in earlier disease settings and in various rational combinations. How can you make the most of these new ADC options in the context of other available therapies, and what is the best way to integrate them into practice? This activity, based on a PeerView Live MasterClass & Practicum educational symposium, addresses these and many other critical questions. By combining insightful analyses of the most recent data with compelling discussions of cases and practicalities, our international expert panel helps you better navigate the complex clinical decisions about when and how to use TROP2-targeting ADCs and the other latest therapies in real-world settings of breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanism of action, evolving clinical role, and latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Integrate personalized treatment plans for patients with breast cancer that takes into consideration the latest evidence and guidelines on TROP2-targeting therapies and relevant treatment-, disease-, and patient-specific factors; and Apply a patient-centered approach to care that incorporates shared decision-making, patient education, and engagement that leverages effective multidisciplinary collaboration and care coordination
  continue reading

497 قسمت

Artwork
iconاشتراک گذاری
 
Manage episode 352264837 series 2771425
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Go online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investigations are underway in earlier disease settings and in various rational combinations. How can you make the most of these new ADC options in the context of other available therapies, and what is the best way to integrate them into practice? This activity, based on a PeerView Live MasterClass & Practicum educational symposium, addresses these and many other critical questions. By combining insightful analyses of the most recent data with compelling discussions of cases and practicalities, our international expert panel helps you better navigate the complex clinical decisions about when and how to use TROP2-targeting ADCs and the other latest therapies in real-world settings of breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanism of action, evolving clinical role, and latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Integrate personalized treatment plans for patients with breast cancer that takes into consideration the latest evidence and guidelines on TROP2-targeting therapies and relevant treatment-, disease-, and patient-specific factors; and Apply a patient-centered approach to care that incorporates shared decision-making, patient education, and engagement that leverages effective multidisciplinary collaboration and care coordination
  continue reading

497 قسمت

همه قسمت ها

×
 
Loading …

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.

 

راهنمای مرجع سریع

در حین کاوش به این نمایش گوش دهید
پخش